



ME/CFS RESEARCH SUMMARY

by Jamie Seltzer

GENERAL INFORMATION

THE INSTITUTE OF MEDICINE REPORT, 2015



[Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness](#) is a literature review conducted by the then-IOM. A panel of experts reviewed over 9,000 separate studies to produce it. It concluded that ME/CFS is a multi-system disease often preceded by an immune challenge.

METABOLISM

- [Fluge and Mella, 2016; Armstrong et al., 2015](#) – Identified errors in cellular energy production in patients, including a reduction in glycolysis, the process that breaks down carbohydrates and sugars. Other energy-producing reactions' metabolites were elevated, which may indicate a kind of metabolic compensation for this dysfunction. For example, amino acids and proteins show signs of being broken down at an accelerated rate. Diet showed no difference in protein intake than in controls, so this could not have been the source of the difference. Bathing normal cells in ME patients' blood serum caused them to show the same metabolic abnormalities as patient cells.
- [Naviaux et al., 2016](#) -- Found significant decreases in metabolites that led to the idea of slowed metabolism in ME/CFS patients overall. He also found changes in important cell membrane compounds, like sphingolipids and cholesterol. Naviaux's group also discovered that they could identify patients 19 times of 20 using a mix of 8 metabolites in women and 13 in men.

MICROBIOME

- [Giloteaux et al., 2016](#) -- Maureen Hanson of Cornell's team ([Giloteaux, 2016](#)) confirmed previous results showing that ME patients have different kinds of gut bacteria than healthy individuals, with specific kinds of bacteria elevated (*Firmicutes* and *Bacteroides*). Blood markers also indicated elevated response to bacteria post-exercise, implying leakage of gut bacteria into the blood.
- [Shukla et al., 2015: Sepsis as a Feature of PEM](#) -- [Shukla et al. \(2015\)](#) found that blood samples collected 15 minutes after exercise showed different bacteria in patients than in controls. These researchers also found that certain bacteria increased in the bloodstream only in patients, and not in healthy controls.



([Shukla et al. 2015 -- Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome \(ME/CFS\)](#))

Other studies have verified dysregulation in the intestinal bacteria in patients ([Frémont, Coomans, Massart, & De Meirlier, 2013](#)).

EXERCISE STUDIES

Numerous studies have found unusual reactions to exercise in ME, including:

- Reduced blood flow to the brain and heart ([Neary et al., 2008](#); [Peterson et al., 1994](#))
- Reduced oxygen uptake in hemoglobin ([Miller et al., 2015](#)) and reduced oxygen use on second-day exercise testing ([Jones et al., 2012](#); [Keller, Pryor, & Giloteaux, 2014](#))
- This oxygen use is not caused by a general lack of physical activity (known as 'deconditioning') ([Vermeulen, & Vermeulen van Eck, 2014](#))

Note that exercise studies are usually only performed on minor or minor-moderate-presenting patients. Many patients are incapable of exercise. Also note that exercise testing, which measures metabolites in the blood through a catheter placed in the artery and may measure breaths in and out, cannot be 'fooled' by poor effort on the part of the patient.

- [Light et al., 2009](#): Gene expression post-exercise -- Light's group found different gene function after exercise in patients, including in genes related to immunity, metabolism, and the nervous system. Genes with increased expression included those responsible for regulating function of the heart, cell death, and inflammation.
- [Snell et al., 2013](#), [Keller et al., 2014](#), and [Vermeulen & Vermeulen, 2014](#): Second-day CPET and VO₂

Post-exertional malaise, or a worsening of all symptoms after exertion, is considered the cardinal features of ME/CFS. However, patients do not always experience the consequences of PEM right away; they may experience a 'crash' 8, 24, or 48 hours after the initial exertion.

Snell et al. (2013) found that, while a single exercise test showed no noticeable differences between CFS patients and controls, a second test performed 24 hours later showed significant abnormalities in oxygen use and how hard patients were able to work. Keller (2014) also found significant differences in ability to perform during a second test.


[Vermeulen et al. \(2014\)](#) compared sedentary controls (active less than 1 hr / week) to ME/CFS patients to show that these findings were not merely a matter of low activity level (deconditioning). O₂ extraction in patients was still found to be less than half of that of inactive controls.

The second-day test is often used to diagnose ME/CFS.

- [PACE trial and refutations](#) -- The PACE trial was a trial of graded exercise therapy for ME/CFS initially heralded as a success. Patients, researchers and clinicians were skeptical of these claims, as The Institute of Medicine describes exercise intolerance as the distinguishing feature of the disease.


Numerous issues with the trial were identified. Most significantly, the original authors found no difference between activity levels on follow-up with the original participants ([Sharpe et al., 2015](#))¹: even the subjective improvements that were reported dissipated within a few months. The same null result was found in their similar FINE trial on long-term follow-up ([Wearden et al., 2010](#)). *The Lancet* has not yet retracted the study, but [PLOS ONE has flagged it](#) and issued an [expression of concern](#).

There have been a series of articles discussing the flaws of the PACE trial, notably David Tuller of Berkeley's series, [Trial By Error](#), posed on Racaniello of Columbia's Virology Blog. Additionally, the Journal of Health Psychology just released a [series of solicited opinions on PACE](#).



NEUROLOGICAL

- [Mathew et al., 2008; 2010; 2012; 2017](#) : Increased ventricular lactate -- Several imaging studies (with a great deal of author overlap) show **increased cerebrospinal lactate** in ME/CFS patients as compared to various control groups. This is significant because lactate is produced by cells when oxygen is low. This implies poor blood flow to the brain in ME patients.
- [Nakatomi et al., 2014](#) : Neuroinflammation -- Nakatomi et al. (2014) performed an imaging study using 11C-(R)PK11195, a protein used to visualize brain inflammation, since it is a marker for damage of



¹ Their abstract reports the opposite to be the case. Reading the full text is necessary.

neurons (brain cells). The ^{11}C -(R)-PK11195 in the brain was between 1.5 and 3 times as high as that of healthy people.

(Right: [Nakatomi et al., 2014 -- Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An \$^{11}\text{C}\$ -\(R\)-PK11195 PET Study](#)
: BP_{ND} of ME/CFS patients versus healthy controls)

- [Shan et al., 2016](#) and [Puri et al., 2012](#): Brain changes on MRI – [Shan et al. \(2016\)](#) found that white matter volume (MWV) had decreased in some regions, and that the grey matter volume (GMV) had decreased in others. These changes correlated to symptoms. [Puri et al., \(2012\)](#) also saw findings on MRI that support patient reports of impaired memory, visual processing, and discrepancies between intended actions and consequent movements.
- [Cook et al., 2017](#) : MRI abnormalities post-exertion -- Patients and healthy controls had similar responses to an initial exercise test, but they could not replicate the level of effort of healthy controls, and they experienced greater pain and fatigue on exertion. Patient response to other tasks was then examined post-exercise. Patients performed significantly worse in difficult mental tasks post-exercise; this impairment could be correlated to changes on MRI.

IMMUNOLOGICAL

The search for a specific virus or bacteria that causes ME has not been successful, although there is evidence that some infections are more likely to result in the illness, including Epstein-Barr Syndrome and other herpes viruses, echovirus, and enterovirus ([Institute of Medicine, 2015](#))². ME/CFS may appear in epidemic outbreaks³, implicating an infectious agent or agents in onset, coupled with a genetic susceptibility; many patients report onset occurs after a severe infection.


- [Cytokine studies](#) – Many cytokines, chemicals related to inflammatory response, have been found to be elevated in patient serum. Some researchers have discovered a general pattern of increased inflammation early in the disease and a more immunosuppressed picture after long-term illness ([Lipkin & Hornig, 2015](#); [Russell et al., 2016](#)). A second set of researchers found that these cytokines fluctuated with severity rather than timecourse ([Montoya et al., 2017](#)).

Right: Russell et al., 2016 – [Illness progression in chronic fatigue syndrome: a shifting immune baseline](#). Different patterns of cytokine expression over disease progression

- [NK function studies](#) – [A summary by Strayer et al. \(2015\)](#) found that out of 17 studies in ME/CFS studying natural killer cell function, 15 had discovered lowered NK cell function in patients. One of the most recent studies on NK function is by [Fletcher et al., 2010](#), who shows a significant difference between NK cell function in healthy controls and patients with ME/CFS.
- [B-cells, T-cells, and Rituximab](#) – One of the most important recent studies showed that Rituximab, a chemotherapy drug, resulted in complete remission for some patients. Accidental discovery in a patient with cancer and ME/CFS led to a phase I, II, and III clinical trial using the drug by [Fluge and Mella](#). The paper posited that the B cell depletion's success provided evidence for ME/CFS as an autoimmune disease. Finally, Curriu and colleagues also found significant elevations of the T cell exhaustion markers PD-1 and CD95 ([2013](#)).

Altered immune reactions to some types of infection have recently been identified in ME in several studies, including a deficiency in EBV-specific B- and T-cell memory response in CFS patients ([Lerner et al., 2012](#)).

- [Autoantibody studies](#) -- Multiple studies have found signs of autoimmunity in ME/CFS patients, including:
 - Elevated ANA
 - Anti-cholinergic muscarinic antibodies ([Loebel et al., 2016](#))
 - B-adrenergic antibodies ([Loebel et al., 2016](#))
 - Anti-serotonin antibodies elevated in nearly 2/3 of patients in a 117 patient study ([Maes et al., 2013](#))
 - Anti-P_i (phosphatidylinositol) antibodies modestly elevated in patients in comparison to healthy controls ([Maes et al., 2007](#))



² You can find a patient-created list of enteroviral research with links [here](#).

³ You can find a list of outbreaks of myalgic encephalomyelitis 1934-1980 with attendant references [here](#).

WORKS CITED

- Armstrong, C.W., McGregor, N.R., Lewis, D.P., Butt, H.L., & Gooley, P.R. (2015, December). Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients. *Metabolomics*, 11(6): 1626-1639.
- Baraniuk, J.N. (2017, July 21). Chronic fatigue syndrome prevalence is grossly overestimated using Oxford criteria compared to Centers for Disease Control (Fukuda) criteria in a U.S. population study. *Fatigue: Biomedicine, Health & Behavior*, 1(16): <http://dx.doi.org/10.1080/21641846.2017.1353578>.
- Barnden, L.R., Crouch, B., Kwiatek, R., Burnet, R., and Del Fante, P. (2015). Evidence in chronic fatigue syndrome for severity-dependent upregulation of prefrontal myelination that is independent of anxiety and depression. *NMR in Biomedicine*, 28(3) 404-413. DOI: 10.1002/nbm.3261
- Barnden, L.R., Kwiatek, R., Crouch, B., Burnet, R., and Del Fante, P. (2016). Autonomic correlations with MRI are abnormal in the brainstem vasomotor centre in Chronic Fatigue Syndrome. *NeuroImage: Clinical*, 11. 530-7. <https://doi.org/10.1016/j.nicl.2016.03.017>
- Boneva RS, Decker MJ, Maloney EM, Lin JM, Jones JF, Helgason HG, Heim CM, Rye DB, Reeves WC. (2007, Dec 30). Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome: a population-based study. *Auton Neurosci.*, 137(1-2):94-101. Epub 2007 Sep 12. PubMed PMID: 17851136.
- Bradley, A. S., Ford, B. and Bansal, A. S. (2013), Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. *Clin Exp Immunol*, 172: 73–80. doi:10.1111/cei.12043
- Brenu, E.W., Huth, T.K., Hardcastle, S.L., Fuller, K., Kaur, M., Johnston, S., Ramos, S.B., Staines, D.R., Marshall-Gradisnik, S.M. (2014 April 1). Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. *INTERNATIONAL IMMUNOLOGY*, 26(4): 233–242. <https://doi.org/10.1093/intimm/dxt068>
- Brown, A. E., Jones, D. E., Walker, M., & Newton, J. L. (2015). Abnormalities of AMPK Activation and Glucose Uptake in Cultured Skeletal Muscle Cells from Individuals with Chronic Fatigue Syndrome. *PLoS ONE*, 10(4), e0122982. <http://doi.org/10.1371/journal.pone.0122982>
- Burgess, M. and Chalder, T. (2004, November). *PACE manual for therapists, Version 2*. Retrieved from: <http://www.wolfson.qmul.ac.uk/images/pdfs/3.cbt-therapist-manual.pdf>
- Carruthers BM, Jain AK, De Meirlier KL, Peterson DL, Klimas NG, Lerner AM, et al. (2003) Myalgic encephalomyelitis/ chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. *J Chronic Fatigue Syndr* 11(1): 7–36. http://doi.org/10.1300/J092v11n01_02
- Carruthers, B. M., van de Sande, M. I., De Meirlier, K. L., Klimas, N. G., Broderick, G., Mitchell, T., ... Stevens, S. (2011). Myalgic encephalomyelitis: International Consensus Criteria. *Journal of Internal Medicine*, 270(4), 327–338. <http://doi.org/10.1111/j.1365-2796.2011.02428.x>
- Cook DB, Light AR, Light KC, Broderick G, Shields MR, Dougherty RJ, Meyer JD, VanRiper S, Stegner AJ, Ellingson LD, Vernon SD. (2017 May). Neural consequences of post-exertion malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Brain Behav Immun*. 62 : 87-99. doi: 10.1016/j.bbi.2017.02.009. Epub 2017 Feb 17. PubMed PMID: 28216087.

Curriu, M., Carrillo, J., Massanella, M., Rigau, J., Alegre, J., Puig, J., ... Blanco, J. (2013). Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. *Journal of Translational Medicine*, 11, 68. <http://doi.org/10.1186/1479-5876-11-68>

Daly, B. (n.d.). Request for information under the Freedom of Information Act 2000 ("the Act") [Letter written December 11, 2015 to James Coyne]. Retrieved July 23, 2017, from <https://dl.dropboxusercontent.com/u/23608059/PACE%20F32515%20-%20Prof.%20James%20Coyne%20-%20Response-2.pdf>

De Vega, W. C., Herrera, S., Vernon, S. D., & McGowan, P. O. (2017). Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *BMC Medical Genomics*, 10, 11. <http://doi.org/10.1186/s12920-017-0248-3>

Di Giorgio A, Hudson M, Jerjes W, Cleare AJ. (2005). 24-hour pituitary and adrenal hormone profiles in chronic fatigue syndrome. *Psychosom Med.*, 67(3):433-40. PubMed PMID: 15911907.

Fletcher, M. A., Zeng, X. R., Maher, K., Levis, S., Hurwitz, B., Antoni, M., ... Klimas, N. G. (2010). Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26. *PLoS ONE*, 5(5), e10817. <http://doi.org/10.1371/journal.pone.0010817>

Fluge, Ø., Bruland, O., Risa, K., Storstein, A., Kristoffersen, E. K., Sapkota, D., ... Mella, O. (2011). Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. *PLoS ONE*, 6(10), e26358. <http://doi.org/10.1371/journal.pone.0026358>

Fluge, Ø., Mella, O., Bruland, O., Risa, K., Dyrstad, S. E., Alme, K., ... Tronstad, K. J. (2016). Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. *JCI Insight*, 1(21), e89376. <http://doi.org/10.1172/jci.insight.89376>

Fluge, Ø., Risa, K., Lunde, S., Alme, K., Rekeland, I. G., Sapkota, D., ... Mella, O. (2015). B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. *PLoS ONE*, 10(7), e0129898. <http://doi.org/10.1371/journal.pone.0129898>

Friedberg, F. (2016, July 7). Cognitive-behavioral therapy: why is it so vilified in the chronic fatigue syndrome community? *Fatigue: Biomedicine, Health & Behavior*, 4(3), 127-131. <http://dx.doi.org/10.1080/21641846.2016.1200884>

Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994). The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med* 121: 953–959.

Gaab J, Engert V, Heitz V, Schad T, Schürmeyer TH, Ehlert U. (2004 Apr). Associations between neuroendocrine responses to the Insulin Tolerance Test and patient characteristics in chronic fatigue syndrome. *J Psychosom Res*, 56(4):419-24. PubMed PMID: 15094026.

Giloteaux, L., Goodrich, J. K., Walters, W. A., Levine, S. M., Ley, R. E., & Hansen, M. R. (2016, June 23). Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. *Microbiome*, 4(30), 1-12. <http://doi.org/10.1186/s40168-016-0171-4>

Goldin, R. (2016, March 21). PACE: The research that sparked a patient rebellion and challenged medicine. In *Sense About Science USA*. Retrieved August 1, 2017, from <http://senseaboutscienceusa.org/pace-research-sparked-patient-rebellionchallenged-medicine/>

Hurum H, Sulheim D, Thaulow E, Wyller VB. (2010, Nov 17). Elevated nocturnal blood pressure and heart rate in adolescent chronic fatigue syndrome. *Acta Paediatr.*, 100(2):289-92. doi: 10.1111/j.1651-2227.2010.02073.x. Epub 2010 Nov 17. PubMed PMID: 21059182.

Huth TK, Breuer EW, Nguyen T, Hardcastle SL, Johnston S, et al. (2014) Characterization of Natural Killer Cell Phenotypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. *J Clin Cell Immunol*, 5(223). doi:10.4172/2155-9899.1000223

IOM (Institute of Medicine). (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies. Retrieved June 21, 2016 from <http://www.nationalacademies.org/hmd/Reports/2015/ME-CFS.aspx>.

Jason LA, Richman JA, Rademaker AW, Jordan KM, Plioplys AV, Taylor RR, McCready W, Huang C, Plioplys S. A Community-Based Study of Chronic Fatigue Syndrome. *Arch Intern Med*. 1999;159(18):2129–2137. doi:10.1001/archinte.159.18.2129

Jiang, Y., Cui, X., Cui, C. et al. (2014). The Function of CD3⁺CD56⁺ NKT-Like Cells in HIV-Infected Individuals. *BioMed Research International*. doi:10.1155/2014/863625

Jones, D.E.J., Hollingsworth, K.G., Jakovljevic, D.G., Fattakhova, G., Pairman, J. Blamire, A.M. ... Newton, J.L. (2012 February). Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. *European Journal of Clinical Investigation*, 42(2), DOI: 10.1111/j.1365-2362.2011.02567.x

Keller, B. A., Pryor, J. L., & Giloteaux, L. (2014). Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO₂ peak indicates functional impairment. *Journal of Translational Medicine*, 12, 104. <http://doi.org/10.1186/1479-5876-12-104>

Koreck, A., Surányi, A., Szöny, B. J., Farkas, Á., Bata-Csörgö, Z., Kemény, L., & Dobozy, A. (2002). CD3⁺CD56⁺ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis. *Clinical and Experimental Immunology*, 127(1), 176–182. <http://doi.org/10.1046/j.1365-2249.2002.01721.x>

Lerner, A. M., Ariza, M. E., Williams, M., Jason, L., Beqaj, S., Fitzgerald, J. T., ... Glaser, R. (2012). Antibody to Epstein-Barr Virus Deoxyuridine Triphosphate Nucleotidohydrolase and Deoxyribonucleotide Polymerase in a Chronic Fatigue Syndrome Subset. *PLoS ONE*, 7(11), e47891. <http://doi.org/10.1371/journal.pone.0047891>

Light, A. R., White, A. T., Hughen, R. W., & Light, K. C. (2009). Moderate exercise increases expression for sensory, adrenergic and immune genes in chronic fatigue syndrome patients, but not in normal subjects. *The Journal of Pain : Official Journal of the American Pain Society*, 10(10), 1099–1112. <http://doi.org/10.1016/j.jpain.2009.06.003>

Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, Meisel C, Reinke P, Volk HD, Fluge Ø, Mella O, Scheibenbogen C. (2016 Feb). Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. *Brain Behav Immun*. 52: 32-9. doi: 10.1016/j.bbi.2015.09.013. Epub 2015 Sep 21. PubMed PMID: 26399744.

Loebel, M., Strohschein, K., Giannini, C., Koelsch, U., Bauer, S., Doebris, C., ... Scheibenbogen, C. (2014). Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome. *PLoS ONE*, 9(1), e85387. <http://doi.org/10.1371/journal.pone.0085387>

Maes M, Mihaylova I, Leunis JC. (2007 December). Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. *Neuro Endocrinol Lett*. 28(6):861-7. PubMed PMID: 18063934.

Maes, M., Ringel, K., Kubera, M., Anderson, G., Morris, G., Galecki, P., Geffard, M. (2013). In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immunoinflammatory pathways and bacterial translocation. *Journal of Affective Disorders*, 150(2):223-30.

Mathew, S.J., Mao, X., Keegan, K.A., Levine, S.M., Smith, E.L., Heier, L.A., Otcheretko, V., Coplan, J.D., and Shungu, D.C. (2009, Apr). Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. *NMR Biomed.* 22(3): 251-8. doi: 10.1002/nbm.1315.

McCook, A. (2016, August 17). UK tribunal orders release of data from controversial chronic fatigue syndrome study. In *Retraction Watch*. Retrieved August 8, 2017, from <http://retractionwatch.com/2016/08/17/uk-tribunal-orders-releaseof-data-from-controversial-chronic-fatigue-syndrome-study/>

ME/CFS Illness Management Survey Results "Our CBT, GET and pacing report calls for major changes to therapies offered for ME/CFS". (2015, May). *ME Association*. Retrieved from <http://www.meassociation.org.uk/2015/05/23959/>

Meeus M, Goubert D, De Backer F, Struyf F, Hermans L, Coppieters I, De Wandele I, Da Silva H, Calders P. (2013, October). Heart rate variability in patients with fibromyalgia and patients with chronic fatigue syndrome: a systematic review. *Semin Arthritis Rheum.*, 43(2):279-87. doi: 10.1016/j.semarthrit.2013.03.004. Epub 2013 Jul 6. Review. PubMed PMID: 23838093.

Miller, R. R., Reid, W. D., Mattman, A., Yamabayashi, C., Steiner, T., Parker, S., ... Patrick, D. M. (2015). Submaximal exercise testing with near-infrared spectroscopy in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients compared to healthy controls: a case-control study. *Journal of Translational Medicine*, 13, 159. <http://doi.org/10.1186/s12967-015-0527-8>

Miwa K, Fujita M. (2011, December). Small heart with low cardiac output for orthostatic intolerance in patients with chronic fatigue syndrome. *Clin Cardiol.*, 34(12):782-6. doi: 10.1002/clc.20962. Epub 2011 Nov 28. PubMed PMID: 22120591.

Miwa K. (2017 Apr). Down-regulation of renin-aldosterone and antidiuretic hormone systems in patients with myalgic encephalomyelitis/chronic fatigue syndrome. *J Cardiol.*, 69(4):684-688. doi: 10.1016/j.jcc.2016.06.003. Epub 2016 Jul 9. PubMed PMID: 27401397.

Montoya, J.G., Holmes, T.H., Anderson, J.N., Maecker, H.T., Rosenberg-Hasson, Y., Valencia, I.J., Chu, L., Younger, J.W., Tato, C.M., and Davis, M.M. (2017 July 31). Cytokine signature associated with disease severity in chronic fatigue syndrome patients. *PNAS Plus*, doi:10.1073/pnas.1710519114

Morris G, Walder K, Puri BK, Berk M, Maes M. (2015 Aug 27). The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: New drug targets in neuroimmune disorders. *Mol Neurobiol.*, 53(7):4638-58. doi: 10.1007/s12035-015-9392-y. PubMed PMID: 26310971.

Murrough, J.W., Mao, X., Collins, K.A., Kelly, C., Andrade, G., Nestadt, P., Levine, S.M., Mathew, S.J., and Shungu, D.C. (2010 July). Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. *NMR Biomed.* 23(6):643-50. doi: 10.1002/nbm.1512.

Naess, H., Nyland, M., Hausken, T., Follestad, I., & Nyland, H. I. (2012). Chronic fatigue syndrome after Giardia enteritis: clinical characteristics, disability and long-term sickness absence. *BMC Gastroenterology*, 12, 13. <http://doi.org/10.1186/1471-230X-12-13>

Natelson, B.H., Vu, D., Coplan, J.D., Mao, X., Blate, M., Kang, G., Soto, E., Kapusuz, T., and Shungu, D.C. (2017 Feb). Elevations of ventricular lactate levels occur in both chronic fatigue syndrome and fibromyalgia. *Fatigue: Biomedicine, Health & Behavior*, 5(1): 15-20. <http://dx.doi.org/10.1080/21641846.2017.1280114>

Navaneetharaja, N., Griffiths, V., Wileman, T., & Carding, S. R. (2016, June 6). A Role for the Intestinal Microbiota and Virome in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)? *Journal of Clinical Medicine*, 55(5), 50-56. doi:10.3390/jcm5060055

Naviaux, R.K., Naviaux, J.C., Li, K., Bright, A.T., Alaynick, W.A., Wang, L. ... Gordon, E. (2016). Metabolic features of chronic fatigue syndrome. *PNAS*, 113(37): E5472-E5480. doi:10.1073/pnas.1607571113

Neary PJ, Roberts AD, Leavins N, Harrison MF, Croll JC, Sexsmith JR. (2008). Prefrontal cortex oxygenation during incremental exercise in chronic fatigue syndrome. *Clin Physiol Funct Imaging*, 28:364–72.

Newton DJ, Kennedy G, Chan KK, Lang CC, Belch JJ, Khan F. (2012, Feb 9). Large and small artery endothelial dysfunction in chronic fatigue syndrome. *Int J Cardiol.*, 154(3):335-6. doi: 10.1016/j.ijcard.2011.10.030. Epub 2011 Nov 10. PubMed PMID: 22078396.

Newton, J. L., Finkelmeyer, A., Petrides, G., Frith, J., Hodgson, T., MacLachlan, L., A.M. Blamire (2016). Reduced cardiac volumes in chronic fatigue syndrome associate with plasma volume but not length of disease: a cohort study. *Open Heart*, 3(1), 398-412. doi:10.1136/openhrt-2015-000381

Okamoto, L. E., Raj, S. R., & Biaggioni, I. (2012). Chronic Fatigue Syndrome and the Autonomic Nervous System. In *Primer on the Autonomic Nervous System* (3rd ed., pp. 531-534). New York: Elsevier Inc.

Oxford Criteria. (n.d.). In *MEpedia*. Retrieved August 5, 2017 from http://me-pedia.org/wiki/Oxford_criteria.

PACE Trial Coordinating Centre. (2008, December). *PACE participants newsletter, Issue 3*. Retrieved from: <http://www.wolfson.qmul.ac.uk/images/pdfs/participantsnewsletter3.pdf>

Pall, M. L. and Satterlee, J. D. (2001), Elevated Nitric Oxide/Peroxynitrite Mechanism for the Common Etiology of Multiple Chemical Sensitivity, Chronic Fatigue Syndrome, and Posttraumatic Stress Disorder. *Annals of the New York Academy of Sciences*, 933: 323–329. doi:10.1111/j.1749-6632.2001.tb05836.x

Perrin, R., Embleton, K., Pentreath, V. W., & Jackson, A. (2010). Longitudinal MRI shows no cerebral abnormality in chronic fatigue syndrome. *The British Journal of Radiology*, 83(989), 419–423. <http://doi.org/10.1259/bjr/85621779>

Peterson, P. K., Sirr, S. A., Grammith, F. C., Schenck, C. H., Pheley, A. M., Hu, S., & Chao, C. C. (1994). Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients. *Clinical and Diagnostic Laboratory Immunology*, 1(2), 222–226.

Puri, B. K., Jakeman, P. M., Agour, M., Gunatilake, K. D. R., Fernando, K. A. C., Gurusinghe, A. I., ... Gishen, P. (2012). Regional grey and white matter volumetric changes in myalgic encephalomyelitis (chronic fatigue syndrome): a voxel-based morphometry 3 T MRI study. *The British Journal of Radiology*, 85(1015), e270–e273. <http://doi.org/10.1259/bjr/93889091>

Russell, L., Broderick, G., Taylor, R., Fernandes, H., Harvey, J., Barnes, Z., ... Fletcher, M. A. (2016). Illness progression in chronic fatigue syndrome: a shifting immune baseline. *BMC Immunology*, 17, 3. <http://doi.org/10.1186/s12865-016-0142-3>

Seltzer, J. B. (2016, August 30). Naviaux's metabolism paper is about as big as you think. In #MEAction - A platform for myalgic encephalomyelitis. Retrieved from <http://www.meaction.net/2016/08/30/naviauxs-metabolism-paper-is-aboutas-big-as-you-think/>

Shan, Z. Y., Kwiatek, R., Burnet, R., Del Fante, P., Staines, D. R., Marshall-Gradisnik, S. M., & Barnden, L. R. (2016). Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study. *Journal of Magnetic Resonance Imaging*, 44(5), 1301–1311. <http://doi.org/10.1002/jmri.25283>

Sharpe, M. et al. (2015, December). Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial. *The Lancet Psychiatry*, 2(12), 1067-1074. [http://www.thelancet.com/journals/lanspy/article/PIIS22150366\(15\)00317-X/fulltext](http://www.thelancet.com/journals/lanspy/article/PIIS22150366(15)00317-X/fulltext)

Shukla, S. K., Cook, D., Meyer, J., Vernon, S. D., Le, T., Clevidence, D., ... Frank, D. N. (2015). Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *PLoS ONE*, 10(12), e0145453. <http://doi.org/10.1371/journal.pone.0145453>

Skowera, A., Stewart, E., Davis, E.T., Cleare, A.J., Unwin, C., Hull, L., ... Peakman, M. (2002). Antinuclear autoantibodies (ANA) in Gulf War-related illness and chronic fatigue syndrome (CFS) patients. *Clinical and Experimental Immunology*, 129(2), 354–358. <http://doi.org/10.1046/j.1365-2249.2002.01912.x>

Shungu, D. C., Weiduschat, N., Murrough, J. W., Mao, X., Pillemer, S., Dyke, J. P., ... Matheu, S. J. (2012). Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. *NMR in Biomedicine*, 25(9), 1073–1087. <http://doi.org/10.1002/nbm.2772>

Snell, C. R., Stevens, S. R., Davenport, T. E., & Van Ness, J. M. (2013, November). Discriminative Validity of Metabolic and Workload Measurements for Identifying People With Chronic Fatigue Syndrome [Electronic version]. *Phys Ther.*, 93(11), 1482-1492. <http://doi.org/10.2522/ptj.20110368>

Strayer D, Scott V, Carter W (2015) Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Symptom Severity. *J Clin Cell Immunol* 6:348. doi:10.4172/2155-9899.1000348

Tanaka S, Kuratsune H, Hidaka Y, Hakariya Y, Tatsumi Ki, Takano T, Kanakura Y, Amino N. (2003 Aug). Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. *Int J Mol Med*, 12(2):225-30. PubMed PMID: 12851722.

Theorell, J., Bileviciute-Ljungar, I., Tesi, B., Schlums, H., Johnsgaard, M. S., Asadi-Azarbaijani, B., ... Bryceson, Y. T. (2017). Unperturbed Cytotoxic Lymphocyte Phenotype and Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. *Frontiers in Immunology*, 8, 723. <http://doi.org/10.3389/fimmu.2017.00723>

Togo, F., & Natelson, B. H. (2013). Heart Rate Variability During Sleep and Subsequent Sleepiness in Patients with Chronic Fatigue Syndrome. *Autonomic Neuroscience : Basic & Clinical*, 176(0), 85–90. <http://doi.org/10.1016/j.autneu.2013.02.015>

Tuller, D., & Rehmeyer, J. (2016, January 7). Trial By Error, Continued: Did the PACE Trial Really Prove that Graded Exercise Is Safe? In *Virology Blog*. Retrieved July 26, 2017, from <http://www.virology.ws/2016/01/07/trial-by-error-continued-didthe-pace-trial-really-prove-that-graded-exercise-is-safe/>

Twisk, F. N. (2015). Accurate diagnosis of myalgic encephalomyelitis and chronic fatigue syndrome based upon objective test methods for characteristic symptoms. *World Journal of Methodology*, 5(2), 68–87. <http://doi.org/10.5662/wjm.v5.i2.68>

Vermeulen, R. C., & Vermeulen van Eck, I. W. (2014). Decreased oxygen extraction during cardiopulmonary exercise test in patients with chronic fatigue syndrome. *Journal of Translational Medicine*, 12, 20. <http://doi.org/10.1186/1479-5876-12-20>

Wearden, A.J., Dowrick, C., Chew-Graham, C., Bentall, R.P., Morriss, R.K., Peters, S. (2010). Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: randomised controlled trial. *BMJ*, 340 :c1777.

White, P., Goldsmith, K., Johnson, A., Potts, L., Walwyn, R., DeCesare, J., ... on behalf of the PACE trial management group. (2011). Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. *Lancet*, 377(9768), 823–836. [http://doi.org/10.1016/S0140-6736\(11\)60096-2](http://doi.org/10.1016/S0140-6736(11)60096-2)

Wilshire, C., Kindlon, T., Matthees, A. & McGrath, S. (2017). Can patients with chronic fatigue syndrome really recover after graded exercise or cognitive behavioural therapy? A critical commentary and preliminary re-analysis of the PACE trial. *Fatigue: Biomedicine, Fatigue & Behavior*. 5(1), 43-56. <http://dx.doi.org/10.1080/21641846.2017.1259724>